Preterm birth remains one of obstetrics' biggest challenges, affecting 4 to 16 percent of pregnancies globally and causing serious complications for newborns. Now, scientists are uncovering exactly how inflammation in the womb triggers early labor, and they're testing a targeted drug approach that could change how doctors prevent it.

What Causes Preterm Birth and Why Does Inflammation Matter?

The fetal membranes, which consist of the amnion and chorion, act as a protective barrier that maintains pregnancy by providing mechanical support and regulating the intrauterine environment. When infection or inflammation damages these membranes, preterm labor can follow. Intrauterine infections are present in approximately 25 to 40 percent of spontaneous preterm births.

The inflammatory response is driven by pro-inflammatory molecules called cytokines, particularly interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). These molecules trigger uterine contractions, cervical ripening, and membrane rupture. IL-1β acts as a key upstream regulator that amplifies inflammatory signaling and promotes the breakdown of the extracellular matrix, which weakens the fetal membranes and can lead to premature rupture.

How Did Researchers Test This New Approach?

Scientists at Rostock University Medical Center in Germany developed a sophisticated laboratory model using actual human fetal membranes collected from term cesarean deliveries. They created a dual-compartment system that allowed them to simulate inflammation on one side of the membrane while measuring inflammatory responses on the other side. This setup mimics what happens in the womb during infection.

The researchers induced inflammation by exposing the membranes to lipopolysaccharide (LPS), a bacterial component that triggers immune responses. They then tested a drug candidate called rytvela, which is designed to selectively modulate the IL-1 receptor and reduce inflammatory signaling without completely shutting down the immune system.

What Were the Key Findings?

The study revealed important time-dependent patterns in how inflammation develops and how the drug works. IL-6 levels became detectable within 6 hours of exposure to LPS, while IL-1β increased at later time points between 24 and 48 hours. This timing difference matters because it suggests different inflammatory pathways activate at different stages.

When researchers tested rytvela at different time points, they found that administering the drug before inflammation started was associated with comparatively lower IL-1β levels compared to giving it at the same time as the inflammatory trigger or after inflammation had already begun. However, IL-6 responses were not consistently affected by rytvela across all experimental conditions.

"The dual-compartment fetal membrane model enables time-resolved analysis of inflammatory responses under physiologically relevant conditions. Preceding administration of rytvela was associated with lower IL-1β levels compared to simultaneous or delayed treatment, whereas IL-6 responses were not consistently affected," noted researchers at Rostock University Medical Center.

Katharina Sterenczak, Department of Obstetrics and Gynecology, Rostock University Medical Center

How to Understand the Clinical Implications

• Preventive Treatment: The findings suggest that giving anti-inflammatory drugs before infection or inflammation develops may be more effective than waiting until symptoms appear, which could change how doctors approach high-risk pregnancies.
• Pathway-Specific Targeting: Because different inflammatory molecules respond differently to treatment, future medications may need to target specific cytokines rather than trying to block all inflammation at once.
• Timing-Dependent Responses: The research demonstrates that the same drug can have different effects depending on when it is administered, highlighting the importance of early intervention in pregnancy complications.

The study used fetal membranes from women undergoing planned cesarean delivery at term, excluding those with complications like preeclampsia, gestational diabetes, maternal infections, or fetal growth restriction. This careful selection ensured the researchers were studying inflammation in isolation without confounding factors.

While this research was conducted in a laboratory model rather than in pregnant women, it provides crucial proof-of-concept evidence that targeted IL-1 modulation could be a viable therapeutic strategy. Previous animal studies in mice and sheep have already shown that rytvela can delay inflammation-induced preterm birth and reduce cytokine-driven tissue injury.

The implications extend beyond just one drug. This research demonstrates that the fetal membrane model itself is a valuable tool for testing how different interventions affect pregnancy-related inflammation. Because the model preserves intact tissue architecture and allows researchers to measure responses from both sides of the membrane, it could accelerate the development of new treatments for preterm birth and other pregnancy complications driven by inflammation.

For expectant parents and healthcare providers, these findings underscore why early detection and management of intrauterine infections is so critical. As research continues to refine our understanding of how inflammation triggers preterm birth, new preventive and therapeutic options may soon become available to protect both mother and baby.